Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$89.76
Market cap
$111.86B
P/E Ratio
897.6
Dividend/share
$3.06
EPS
$0.1
Enterprise value
$130.08B
Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the
Highlights
Gilead Sciences's debt has decreased by 7% YoY
GILD's revenue is up by 3.3% year-on-year
The quick ratio has grown by 19% from the previous quarter but it has contracted by 16% YoY
GILD's EPS has dropped by 98% year-on-year and by 88% since the previous quarter
The company's net income has shrunk by 98% YoY and by 88% QoQ
Key stats
What are the main financial stats of GILD
Market
Valuations
Earnings
Shares outstanding
1.25B
Market cap
$111.86B
Enterprise value
$130.08B
Price to earnings (P/E)
897.6
Price to book (P/B)
6.05
Price to sales (P/S)
3.96
EV/EBIT
111.18
EV/EBITDA
33.08
EV/Sales
4.6
Revenue
$28.3B
EBIT
$1.17B
EBITDA
$3.93B
Free cash flow
$9.43B
Per share
Balance sheet
Liquidity
EPS
$0.1
Free cash flow per share
$7.56
Book value per share
$14.84
Revenue per share
$22.69
TBVPS
$20.58
Total assets
$54.53B
Total liabilities
$36.14B
Debt
$23.25B
Equity
$18.48B
Working capital
$3.05B
Debt to equity
1.26
Current ratio
1.26
Quick ratio
0.82
Net debt/EBITDA
4.63
Margins
Efficiency
Dividend
EBITDA margin
13.9%
Gross margin
76.1%
Net margin
0.4%
Operating margin
2.9%
Return on assets
0.2%
Return on equity
0.7%
Return on invested capital
3.6%
Return on capital employed
2.7%
Return on sales
4.1%
Dividend yield
3.41%
DPS
$3.06
Payout ratio
3,060%
GILD stock price
How has the Gilead Sciences stock price performed over time
Intraday
1.27%
1 week
-2.55%
1 month
4.02%
1 year
20.18%
YTD
10.8%
QTD
7.06%
Financial performance
How have Gilead Sciences's revenue and profit performed over time
Revenue
$28.3B
Gross profit
$21.54B
Operating income
$821M
Net income
$126M
Gross margin
76.1%
Net margin
0.4%
Gilead Sciences's net margin has shrunk by 98% YoY and by 89% QoQ
The company's net income has shrunk by 98% YoY and by 88% QoQ
The operating margin has plunged by 90% YoY and by 68% from the previous quarter
The operating income has dropped by 90% year-on-year and by 68% since the previous quarter
Growth
What is Gilead Sciences's growth rate over time
Valuation
What is Gilead Sciences stock price valuation
P/E
897.6
P/B
6.05
P/S
3.96
EV/EBIT
111.18
EV/EBITDA
33.08
EV/Sales
4.6
GILD's EPS has dropped by 98% year-on-year and by 88% since the previous quarter
The stock's price to book (P/B) is 38% more than its 5-year quarterly average of 4.4 and 21% more than its last 4 quarters average of 5.0
Gilead Sciences's equity has decreased by 17% YoY
GILD's price to sales (P/S) is 16% more than its 5-year quarterly average of 3.4 and 13% more than its last 4 quarters average of 3.5
GILD's revenue is up by 3.3% year-on-year
Efficiency
How efficient is Gilead Sciences business performance
GILD's return on assets has dropped by 98% year-on-year and by 89% since the previous quarter
The company's return on equity has shrunk by 97% YoY and by 87% QoQ
GILD's return on sales has dropped by 86% year-on-year and by 55% since the previous quarter
Gilead Sciences's ROIC has plunged by 85% YoY and by 53% from the previous quarter
Dividends
What is GILD's dividend history
DPS
$3.06
Dividend yield
3.41%
Payout ratio
3,060%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Gilead Sciences financials performed over time
GILD's total assets is 51% higher than its total liabilities
The quick ratio has grown by 19% from the previous quarter but it has contracted by 16% YoY
GILD's total assets is down by 13% YoY
Gilead Sciences's debt is 26% higher than its equity
Gilead Sciences's equity has decreased by 17% YoY
The company's debt to equity rose by 13% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.